TRIM33 and breast cancer: Nineteen of 51 (37.3%) of the anti-TIF1γ adult myositis patients had CAM, with seven cases of breast cancer, three ovarian, two lymphoma, and single cases of bowel, hepatic, leukaemia, lung, melanoma, myeloma and oesophageal cancer reported.